<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ja">
	<id>https://www.xn--3dkvalq0cx455coz1c.com/wiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=LandonMonash165</id>
	<title>ワンルーム投資 Wiki - 利用者の投稿記録 [ja]</title>
	<link rel="self" type="application/atom+xml" href="https://www.xn--3dkvalq0cx455coz1c.com/wiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=LandonMonash165"/>
	<link rel="alternate" type="text/html" href="https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php/%E7%89%B9%E5%88%A5:%E6%8A%95%E7%A8%BF%E8%A8%98%E9%8C%B2/LandonMonash165"/>
	<updated>2026-11-21T16:39:59Z</updated>
	<subtitle>利用者の投稿記録</subtitle>
	<generator>MediaWiki 1.40.3</generator>
	<entry>
		<id>https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php?title=Levofloxacin:_A_Comprehensive_Review_Of_Its_Pharmacological_Profile,_Clinical_Applications,_And_Resistance_Challenges&amp;diff=3645</id>
		<title>Levofloxacin: A Comprehensive Review Of Its Pharmacological Profile, Clinical Applications, And Resistance Challenges</title>
		<link rel="alternate" type="text/html" href="https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php?title=Levofloxacin:_A_Comprehensive_Review_Of_Its_Pharmacological_Profile,_Clinical_Applications,_And_Resistance_Challenges&amp;diff=3645"/>
		<updated>2026-04-23T23:09:10Z</updated>

		<summary type="html">&lt;p&gt;LandonMonash165: ページの作成:「&amp;lt;br&amp;gt;Levofloxacin, the pharmacologically active L-isomer of ofloxacin, represents a cornerstone in the arsenal of modern fluoroquinolone antibiotics. Since its introduction in the 1990s, it has been widely prescribed for a broad spectrum of bacterial infections due to its potent bactericidal activity, excellent bioavailability, and favorable tissue penetration. This article provides a comprehensive review of levofloxacin, encompassing its mechanism of action, pharmac…」&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;Levofloxacin, the pharmacologically active L-isomer of ofloxacin, represents a cornerstone in the arsenal of modern fluoroquinolone antibiotics. Since its introduction in the 1990s, it has been widely prescribed for a broad spectrum of bacterial infections due to its potent bactericidal activity, excellent bioavailability, and favorable tissue penetration. This article provides a comprehensive review of levofloxacin, encompassing its mechanism of action, pharmacokinetic properties, spectrum of activity, established clinical uses, adverse effect profile, and the growing challenge of antimicrobial resistance.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;1. Mechanism of Action and Pharmacokinetics&amp;lt;br&amp;gt;Levofloxacin exerts its bactericidal effect primarily through the inhibition of two essential bacterial type II topoisomerase enzymes: DNA gyrase and topoisomerase IV. DNA gyrase is responsible for introducing negative supercoils into DNA, crucial for DNA replication and transcription, while topoisomerase IV decatenates interlinked daughter chromosomes post-replication. By binding to the enzyme-DNA complex, levofloxacin stabilizes it, preventing the religation of DNA strands. This action leads to the generation of double-stranded DNA breaks, rapid cessation of bacterial DNA synthesis, and ultimately, cell death.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Pharmacokinetically, levofloxacin is characterized by near-complete oral bioavailability (approximately 99%), allowing for seamless transition between intravenous and oral formulations without dosage adjustment—a feature known as sequential therapy. It demonstrates linear pharmacokinetics, with peak plasma concentrations achieved within 1-2 hours post-adoral administration. The drug exhibits low plasma protein binding (24-38%) and a volume of distribution that exceeds total body water, indicating extensive tissue penetration. It achieves high concentrations in respiratory tissues, prostate, skin, and urine. Levofloxacin undergoes limited hepatic metabolism, with the majority (over 85%) excreted unchanged in the urine via glomerular filtration and tubular secretion, resulting in a half-life of approximately 6-8 hours in patients with normal renal function. Dosage adjustment is therefore imperative in renal impairment.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;2. Antimicrobial Spectrum&amp;lt;br&amp;gt;Levofloxacin is classified as a respiratory fluoroquinolone due to its enhanced activity against typical and atypical respiratory pathogens. Its spectrum is broad, encompassing a wide range of Gram-positive, Gram-negative, and atypical bacteria.&amp;lt;br&amp;gt;Gram-positive bacteria: It is active against Streptococcus pneumoniae (including penicillin-resistant strains), Staphylococcus aureus (methicillin-susceptible), and Enterococcus faecalis.&amp;lt;br&amp;gt;Gram-negative bacteria: It demonstrates excellent activity against members of the Enterobacteriaceae family (e.g., Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis), as well as Haemophilus influenzae and Moraxella catarrhalis. It also has activity against Pseudomonas aeruginosa, though resistance is common and susceptibility testing is mandatory.&amp;lt;br&amp;gt;Atypical pathogens: Levofloxacin is highly active against intracellular and atypical organisms, including Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae.&amp;lt;br&amp;gt;Others: It possesses activity against certain mycobacteria, notably Mycobacterium tuberculosis and Mycobacterium avium complex, making it a valuable component in anti-tuberculosis regimens, particularly for drug-resistant cases.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;3. Established Clinical Applications&amp;lt;br&amp;gt;Levofloxacin is indicated for the treatment of various community-acquired and healthcare-associated infections, guided by its pharmacokinetic and pharmacodynamic (PK/PD) profile, where the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) is the primary determinant of efficacy.&amp;lt;br&amp;gt;Community-Acquired Pneumonia (CAP): It is a first-line agent for moderate to severe CAP, effective against the most common causative pathogens, including drug-resistant S. pneumoniae and atypicals.&amp;lt;br&amp;gt;Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) and Acute Bacterial Sinusitis: Its potent respiratory activity makes it a standard choice.&amp;lt;br&amp;gt;Complicated and Uncomplicated Urinary Tract Infections (UTIs) and Pyelonephritis: High urinary concentrations render it effective for these indications, including cases caused by multidrug-resistant uropathogens.&amp;lt;br&amp;gt;Skin and Skin Structure Infections: It is used for complicated infections, often in combination with an agent active against anaerobic bacteria.&amp;lt;br&amp;gt;Prostatitis: Its excellent penetration into prostatic tissue makes it a preferred option for chronic bacterial prostatitis.&amp;lt;br&amp;gt;Other Uses: It is a component of multidrug regimens for multidrug-resistant tuberculosis (MDR-TB) and used for prophylaxis and treatment of inhalational anthrax (Bacillus anthracis).&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;4. Adverse Effects and Safety Considerations&amp;lt;br&amp;gt;While generally well-tolerated, levofloxacin carries class-specific and unique safety warnings. Common adverse effects include gastrointestinal disturbances (nausea, diarrhea), central nervous system effects (headache, dizziness, insomnia), and mild phototoxicity. However, several serious adverse reactions warrant careful patient selection and monitoring.&amp;lt;br&amp;gt;Tendinopathy and Tendon Rupture: Risk is increased in patients over 60, those on concomitant corticosteroids, and solid organ transplant recipients. The Achilles tendon is most commonly affected.&amp;lt;br&amp;gt;Peripheral Neuropathy: Potentially irreversible sensory or sensorimotor axonal polyneuropathy can occur rapidly.&amp;lt;br&amp;gt;Central Nervous System Effects: Serious events like seizures, psychosis, and increased intracranial pressure have been reported.&amp;lt;br&amp;gt;QTc Interval Prolongation: Levofloxacin can prolong the cardiac QT interval, posing a risk of torsades de pointes, particularly in patients with underlying cardiac conditions or those taking other QT-prolonging drugs.&amp;lt;br&amp;gt;Hypoglycemia and Hyperglycemia: Significant dysglycemia, especially in diabetic patients, has been observed.&amp;lt;br&amp;gt;Other Concerns: These include hepatic toxicity, Clostridioides difficile-associated diarrhea, and aortic aneurysm/dissection risk. Due to potential cartilage damage observed in juvenile animals, its use is generally avoided in pediatric patients and pregnant women unless no alternative exists.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;5. The Mounting Challenge of Antimicrobial Resistance&amp;lt;br&amp;gt;The widespread and sometimes inappropriate use of fluoroquinolones has led to a significant and alarming increase in bacterial resistance, threatening the clinical utility of levofloxacin. Resistance mechanisms are primarily chromosomal and include:&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Target-Site Mutations: Alterations in the gyrA and parC genes encoding DNA gyrase and topoisomerase IV, respectively, reduce the binding affinity of the drug.&amp;lt;br&amp;gt;Efflux Pump Upregulation: Increased expression of multidrug efflux pumps (e.g., AcrAB-TolC in Enterobacteriaceae) actively expels the antibiotic from the bacterial cell.&amp;lt;br&amp;gt;Plasmid-Mediated Resistance: Although less common than with other antibiotic classes, plasmids carrying genes like qnr (which protect topoisomerases) and aac(6')-Ib-cr (which acetylates and inactivates the drug) can facilitate horizontal transfer of resistance.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This resistance is particularly prevalent in E. coli causing UTIs and in P. aeruginosa. Consequently, empirical use of levofloxacin is no longer [https://www.tumblr.com/search/recommended recommended] for  Revisión Basada en Evidencia [[https://corazondecarcar.es/geriforte-soporte-integral-para-el-estrs-y-la-vitalidad-revisin-basada-en-eviden/ corazondecarcar.es]] uncomplicated cystitis in many regions, and its use must be guided by culture and susceptibility testing whenever possible.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Conclusion&amp;lt;br&amp;gt;Levofloxacin remains a potent and valuable broad-spectrum antibiotic with definitive roles in treating serious respiratory, urinary, and other systemic infections. Its favorable pharmacokinetics allow for convenient once-daily dosing and IV-to-oral switch therapy. However, its clinical application is now tightly constrained by a well-documented profile of serious, albeit rare, adverse effects and, more pressingly, by the relentless rise in bacterial resistance. Prudent use, strict adherence to indicated guidelines, routine susceptibility testing, and integration into antimicrobial stewardship programs are essential to preserve its efficacy for future generations. The story of levofloxacin underscores the delicate balance between harnessing powerful antimicrobial tools and safeguarding their longevity in the face of evolving microbial threats.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>LandonMonash165</name></author>
	</entry>
	<entry>
		<id>https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php?title=Comprehensive_Study_Report_On_Floxin_(Ofloxacin):_Pharmacology,_Clinical_Applications,_And_Safety_Profile&amp;diff=3629</id>
		<title>Comprehensive Study Report On Floxin (Ofloxacin): Pharmacology, Clinical Applications, And Safety Profile</title>
		<link rel="alternate" type="text/html" href="https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php?title=Comprehensive_Study_Report_On_Floxin_(Ofloxacin):_Pharmacology,_Clinical_Applications,_And_Safety_Profile&amp;diff=3629"/>
		<updated>2026-04-23T22:15:54Z</updated>

		<summary type="html">&lt;p&gt;LandonMonash165: ページの作成:「&amp;lt;br&amp;gt;Floxin, known generically as ofloxacin, is a synthetic broad-spectrum fluoroquinolone antibiotic. First approved for medical use in the 1980s, it has been a significant agent in the antimicrobial arsenal for treating various bacterial infections. This report provides a detailed examination of Floxin, encompassing its pharmacological properties, spectrum of activity, clinical applications, resistance mechanisms, adverse effects, and its current place in therapy.&amp;lt;…」&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;Floxin, known generically as ofloxacin, is a synthetic broad-spectrum fluoroquinolone antibiotic. First approved for medical use in the 1980s, it has been a significant agent in the antimicrobial arsenal for treating various bacterial infections. This report provides a detailed examination of Floxin, encompassing its pharmacological properties, spectrum of activity, clinical applications, resistance mechanisms, adverse effects, and its current place in therapy.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;1. Pharmacological Properties and Mechanism of Action&amp;lt;br&amp;gt;Ofloxacin is a second-generation fluoroquinolone. Its bactericidal action stems from the inhibition of two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. DNA gyrase is crucial for supercoiling bacterial DNA during replication, while topoisomerase IV is involved in separating daughter chromosomes post-replication. By binding to these enzymes, ofloxacin stabilizes the DNA-enzyme complex, preventing the resealing of DNA strands. This leads to the formation of double-strand DNA breaks, rapid cessation of DNA synthesis, and ultimately, bacterial cell death.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Pharmacokinetically, ofloxacin is well-absorbed orally with a bioavailability exceeding 95%. It demonstrates excellent tissue penetration, achieving concentrations in various body fluids and tissues (including prostate, lung, and skin) that often exceed serum levels. Its volume of distribution is high. Ofloxacin is metabolized to a limited extent in the liver and is primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion, resulting in a half-life of approximately 5-7 hours in adults with normal renal function. This renal excretion necessitates dosage adjustment in patients with significant renal impairment.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;2. Antimicrobial Spectrum&amp;lt;br&amp;gt;Floxin exhibits a broad spectrum of activity against both Gram-positive and Gram-negative bacteria, though it is generally more potent against the latter. Its spectrum includes:&amp;lt;br&amp;gt;Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Neisseria gonorrhoeae, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa (moderate activity), and many Enterobacteriaceae.&amp;lt;br&amp;gt;Gram-positive bacteria: Staphylococcus aureus (including methicillin-sensitive strains), Streptococcus pneumoniae (with variable susceptibility), and Streptococcus pyogenes.&amp;lt;br&amp;gt;Atypical pathogens: It is notably active against Chlamydia trachomatis, Mycoplasma pneumoniae, and Ureaplasma urealyticum. It also has activity against Mycobacterium tuberculosis and some mycobacteria, and certain anaerobic bacteria, though it is not a first-line agent for anaerobic infections.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;3. Clinical Applications&amp;lt;br&amp;gt;Floxin has been historically used to treat a range of infections, though its use has become more restricted in recent years due to safety concerns and the availability of other agents. Its FDA-approved indications have included:&amp;lt;br&amp;gt;Respiratory Tract Infections: Including acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia (though not first-line for pneumococcal pneumonia).&amp;lt;br&amp;gt;Urinary Tract Infections (UTIs): Complicated and uncomplicated cystitis and pyelonephritis caused by susceptible organisms.&amp;lt;br&amp;gt;Sexually Transmitted Infections (STIs): Particularly for uncomplicated cervical and urethral gonorrhea (as monotherapy or in combination) and non-gonococcal urethritis/cervicitis caused by C. trachomatis.&amp;lt;br&amp;gt;Skin and Skin Structure Infections: Uncomplicated infections caused by susceptible staphylococci and streptococci.&amp;lt;br&amp;gt;Prostatitis: Chronic bacterial prostatitis due to E. coli.&amp;lt;br&amp;gt;Ophthalmic Infections: A topical formulation is used for conjunctivitis and corneal ulcers.&amp;lt;br&amp;gt;Traveler's Diarrhea: Caused by enterotoxigenic E. coli and Campylobacter jejuni.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;4. Resistance Mechanisms&amp;lt;br&amp;gt;Bacterial resistance to ofloxacin, as with other fluoroquinolones, can develop through several mechanisms:&amp;lt;br&amp;gt;Chromosomal Mutations: The primary mechanism involves mutations in the genes encoding the target enzymes (DNA gyrase, primarily gyrA and gyrB; and topoisomerase IV, parC and parE). These mutations reduce the binding affinity of the drug.&amp;lt;br&amp;gt;Efflux Pump Upregulation: Increased expression of multidrug efflux pumps (e.g., in Pseudomonas aeruginosa) actively expels the antibiotic from the bacterial cell, decreasing intracellular concentration.&amp;lt;br&amp;gt;Plasmid-Mediated Resistance: Though less common for fluoroquinolones, plasmids carrying genes like qnr (which protect DNA gyrase) can confer low-level resistance and facilitate the selection of higher-level chromosomal mutations.&amp;lt;br&amp;gt;Resistance is often stepwise, with initial low-level resistance escalating with additional mutations, leading to cross-resistance within the fluoroquinolone class.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;5. Adverse Effects and Safety Concerns&amp;lt;br&amp;gt;The use of Floxin is associated with a range of potential adverse effects, some of which are class-wide for fluoroquinolones and have led to significant regulatory restrictions.&amp;lt;br&amp;gt;Musculoskeletal Effects: Tendinitis and tendon rupture, particularly of the Achilles tendon, are well-documented, serious risks. The risk is increased in the elderly, those on corticosteroid therapy, and kidney, heart, or lung transplant recipients. Arthralgia and myalgia are also common.&amp;lt;br&amp;gt;Neurotoxic Effects: Central nervous system effects include dizziness, insomnia, headache, and, rarely, seizures (lower risk than with some earlier fluoroquinolones). Peripheral neuropathy, characterized by pain, burning, tingling, or weakness, can be irreversible.&amp;lt;br&amp;gt;Gastrointestinal Effects: Nausea, diarrhea, vomiting, and abdominal discomfort are relatively common.&amp;lt;br&amp;gt;Cardiovascular Effects: QT interval prolongation on the electrocardiogram, which can predispose to ventricular arrhythmias like torsades de pointes, especially when co-administered with other QT-prolonging drugs.&amp;lt;br&amp;gt;Hypersensitivity Reactions: Rashes, photosensitivity, and, rarely, severe reactions like Stevens-Johnson syndrome.&amp;lt;br&amp;gt;Other Effects: Hepatotoxicity, blood glucose disturbances, and Clostridioides difficile*-associated diarrhea.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Due to these risks,  [https://rache.es/producto/hsquin/ https://rache.es]] particularly the disabling and potentially permanent side effects involving tendons, muscles, joints, nerves, and the central nervous system, regulatory agencies like the U.S. FDA and EMA have issued strong warnings. Fluoroquinolones, including ofloxacin, are now reserved for use in patients who have no alternative treatment options for uncomplicated infections (like acute bronchitis, sinusitis, and uncomplicated UTIs).&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;6. Conclusion and Current Therapeutic Role&amp;lt;br&amp;gt;Floxin (ofloxacin) represents an important chapter in the history of antimicrobial chemotherapy. Its broad spectrum, excellent oral bioavailability, and tissue penetration made it a versatile agent for two decades. However, the recognition of its potential for causing severe, sometimes irreversible adverse effects has drastically altered its risk-benefit profile.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;In contemporary clinical practice, systemic ofloxacin use has been largely supplanted by other fluoroquinolones with improved spectra (e.g., levofloxacin, moxifloxacin) for specific indications, and more importantly, by non-fluoroquinolone agents for many common infections. Its current role is highly circumscribed. It remains a useful option in specific scenarios where the causative organism is known to be susceptible, no safer alternative exists, and the benefits clearly outweigh the risks—such as in certain cases of multidrug-resistant tuberculosis (as part of a regimen) or [https://de.bab.la/woerterbuch/englisch-deutsch/complicated%20UTIs complicated UTIs] with proven susceptibility. The topical ophthalmic formulation continues to be a valuable tool for treating bacterial eye infections with a favorable local safety profile.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;In summary, while Floxin is an effective antibacterial agent, its systemic use is now [https://www.thesaurus.com/browse/heavily%20restricted heavily restricted]. Its history underscores the critical importance of post-marketing surveillance and the evolving nature of risk assessment in pharmacotherapy. Prescribers must exercise stringent clinical judgment, adhering to updated guidelines that emphasize reserving fluoroquinolones for serious infections where alternative treatments are not suitable.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>LandonMonash165</name></author>
	</entry>
	<entry>
		<id>https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php?title=%E5%88%A9%E7%94%A8%E8%80%85:LandonMonash165&amp;diff=3628</id>
		<title>利用者:LandonMonash165</title>
		<link rel="alternate" type="text/html" href="https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php?title=%E5%88%A9%E7%94%A8%E8%80%85:LandonMonash165&amp;diff=3628"/>
		<updated>2026-04-23T22:15:42Z</updated>

		<summary type="html">&lt;p&gt;LandonMonash165: ページの作成:「Hi there! :) My name is Lashay, I'm a student studying Chemistry from Lambersart, France.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;My blog post 400 mg desde €0.43 ���� — Hydroxychloroquine https://rache.es/producto/hsquin/ https://rache.es」&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Hi there! :) My name is Lashay, I'm a student studying Chemistry from Lambersart, France.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;My blog post 400 mg desde €0.43 ���� — Hydroxychloroquine [[https://rache.es/producto/hsquin/ https://rache.es]]&lt;/div&gt;</summary>
		<author><name>LandonMonash165</name></author>
	</entry>
</feed>